ライフサイエンスコーパス: psychotomimetic

1 of ketamine, an NMDA receptor antagonist and psychotomimetic.

2 rough the previously investigated targets of psychotomimetics.

3 c dysfunction in animal and human studies, a psychotomimetic agent and a rapidly acting antidepressan

4 Nonetheless, its use is limited due to its psychotomimetic and addictive properties.

5 Ketamine is a psychotomimetic and antidepressant drug.

6 of these drugs, the main mechanism for their psychotomimetic and cognitive-impairing effects has been

7 ulation, may be necessary to account for the psychotomimetic and cognitive-impairing effects of this

8 7-78.49), respectively, accompanied by brief psychotomimetic and dissociative effects.

9 s to produce antidepressant efficacy without psychotomimetic and dissociative side effects.

10 ly gained significant attention owing to its psychotomimetic and more recently discovered rapid antid

11 ns, regulating the response to neuroleptics, psychotomimetics, and drugs of abuse, and affecting stri

12 phic gamma band power, possibly reflecting a psychotomimetic aspect of ketamine's effect, and is cont

13 y measured in the ventral tegmental area and psychotomimetic behavioral analyses.

14 Potential psychotomimetic, dissociative, hemodynamic, and general

15 A single sub-psychotomimetic dose of ketamine, an ionotropic glutamat

16 s prompted investigations into the nature of psychotomimetic drug effects on PFC neuronal activity.

17 ithin PV+ cells, reversibly inhibited by the psychotomimetic drug ketamine, play a critical role in S

18 The effects of the psychotomimetic drug phencyclidine on the neurochemistry

19 studies demonstrated differential effects of psychotomimetic drugs (cocaine and methamphetamine) on n

20 onists also modulate the in vivo activity of psychotomimetic drugs and reduce the ability of psychoto

21 attempts to reliably induce a PPI deficit by psychotomimetic drugs have not been successful, leaving

22 s including prepulse inhibition, response to psychotomimetic drugs, and social interaction.

23 tamine but qualitatively distinct from other psychotomimetic drugs, including ketamine, amphetamine,

24 The psychotomimetic effect of the N-methyl-D-aspartate recep

25 Psychotomimetic effects (Positive and Negative Syndrome

26 impairing (delayed-matching-to-position), or psychotomimetic effects (specifically, phencyclidine dis

27 a rapid-acting antidepressant devoid of the psychotomimetic effects and abuse potential of ketamine.

28 SA produced psychotomimetic effects and perceptual alterations, incl

29 c acid/glutamate receptor antagonists induce psychotomimetic effects in humans and animals, and much

30 orking memory on a CogState battery; and (3) psychotomimetic effects measured by the Positive and Neg

31 This is consistent with the absence of psychotomimetic effects observed for this class of drugs

32 provide a plausible mechanism underlying the psychotomimetic effects of cannabinoids.

33 reases in neural noise may contribute to the psychotomimetic effects of Delta(9)-THC.

34 t neural noise could also be involved in the psychotomimetic effects of delta-9-tetrahydrocannabinol

35 en implicated in psychiatric illness and the psychotomimetic effects of hallucinogens.

36 of various lines of evidence, including the psychotomimetic effects of NMDA receptor antagonists.

37 Specifically, we review data on the psychotomimetic effects of sleep deprivation in healthy

38 However, ketamine can also produce psychotomimetic effects that limit its utility as an ant

39 BA deficit would create vulnerability to the psychotomimetic effects to the 'subthreshold' dose of AM

40 d but short-lived antidepressant effects; no psychotomimetic effects were observed.

41 Concomitantly, Delta(9)-THC induced psychotomimetic effects, perceptual alterations, and sub

42 to the magnitude and spectrum of their acute psychotomimetic effects.

43 t significantly attenuating ketamine-induced psychotomimetic effects.

44 e frequency and severity of dissociative and psychotomimetic effects.

45 channel blocker with low rates of associated psychotomimetic effects.

46 d by its abuse potential as well as possible psychotomimetic effects.

47 chotomimetic drugs and reduce the ability of psychotomimetic hallucinogens to increase glutamatergic

48 alterations both in sensorimotor gating and psychotomimetic-induced locomotor activity.

49 Systemic doses of the psychotomimetic ketamine alter the spectral characterist

50 Glu5 NAM MTEP across models of addiction and psychotomimetic-like activity.

51 e effects, including psychosis in humans and psychotomimetic-like effects in animals, suggesting a na

52 erbation was induced with an infusion of the psychotomimetic methylphenidate hydrochloride (0.5 mg/kg

53 s observed between the groups with regard to psychotomimetic or dissociative adverse effects.

54 sal ketamine was well tolerated with minimal psychotomimetic or dissociative effects and was not asso

55 ficantly reduced depressive symptoms without psychotomimetic or dissociative effects.

56 to represent spatial knowledge, we used the psychotomimetic phencyclidine (PCP) to disrupt cognitive

57 We used the psychotomimetic phencyclidine (PCP) to investigate the r

58 of the NMDA/glutamate receptor, such as the psychotomimetic phencyclidine (PCP).

59 The psychotomimetic phencyclidine and its potent congener di

60 receptor antagonist phencyclidine (PCP) has psychotomimetic properties in humans and activates the f

61 ntal cortex (PFC) neurons in reinforcing and psychotomimetic properties of psychostimulants, yet litt

62 exerts rapid antidepressant effects but has psychotomimetic properties.

63 Because Salvinorin A is a psychotomimetic selective for kappa opioid receptors, ka

64 oral responses may be related to the lack of psychotomimetic side effects of GLYX-13 compared with ke

65 apid antidepressant effects, but without the psychotomimetic side effects of ketamine.

66 d limited clinical value due to debilitating psychotomimetic side-effects.

67 line of thinking is that these drugs create psychotomimetic states by similarly disinhibiting the ac

68 atergic antagonists (such as PCP) all induce psychotomimetic states in experimental animals that clos

69 I and self-reported psychosis-like symptoms (Psychotomimetic States Inventory) were measured in 24 he

70 ine metabolites and response, diagnosis, and psychotomimetic symptoms in MDD and BD patients.